| Identification | Back Directory | [Name]
3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE | [CAS]
18741-24-7 | [Synonyms]
AKOS BBS-00007268
PDE7 inhibitor S14
PDE7 inhibitor-S14
TIMTEC-BB SBB000936
3-phenyl-2-thioxo-1H-quinazolin-4-one
PDE-7 inhibitor S14,PDE7 inhibitor S14
2-mercapto-3-phenylquinazolin-4(3H)-one
3-Phenyl-2(1H)-thioxoquinazoline-4(3H)-one
1,3-dihydro-3-phenyl-2-thio-quinazolin-4-on
2-Thio-3-phenyl-1,3-dihydroquinazolin-4-one
3-phenyl-2-sulfanylidene-1H-quinazolin-4-one
3-Phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin
Quinazolin-4-one, 1,3-dihydro-3-phenyl-2-thio-
3-Phenyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one
3-PHENYL-2-THIOXO-2,3-DIHYDRO-4(1H)-QUINAZOLINONE
2,3-dihydro-3-phenyl-2-thioxoquinazolin-4(1H)-one
3-Phenyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one
1,2-DIHYDRO-3-PHENYL-2-THIOXO-4(3H)-QUINAZOLINONE
2-Thioxo-1,2-dihydro-3-phenylquinazoline-4(3H)-one
3-Phenyl-2-thioxo-1,2-dihydroquinazoline-4(3H)-one
4(1H)-Quinazolinone,2,3-dihydro-3-phenyl-2-thioxo-
3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE
3-Phenyl-1,2,3,4-tetrahydro-2-thioxoquinazolin-4-one
1,2,3,4-Tetrahydro-3-phenyl-2-thioxoquinazoline-4-one
4-Oxo-3-phenyl-1,2,3,4-tetrahydro-2-thioxoquinazoline | [EINECS(EC#)]
242-550-6 | [Molecular Formula]
C14H10N2OS | [MDL Number]
MFCD00023895 | [MOL File]
18741-24-7.mol | [Molecular Weight]
254.31 |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [HazardClass ]
IRRITANT | [HS Code ]
2933998090 | [Toxicity]
mouse,LD50,intravenous,180mg/kg (180mg/kg),U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#04508, |
| Hazard Information | Back Directory | [Uses]
PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases[1]. | [References]
[1] Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles DOI:10.3390/ijms22063206 |
|
|